Often, when a new class of drugs receives FDA approval, we hear from the investigators or medical professionals involved in the original studies and clinical trials and, although they may possess the most knowledge, they are often the least likely to fairly represent the opinions of most medical professionals. For …
Read More »AACE Presentations of SGLT-2 Inhibitor Data
David Joffe, BSPharm, CDE, Editor-in-chief, Diabetes In Control Lauren Self, University of Florida College of Pharmacy, PharmD Candidate When the finest, most talented endocrinologists get together for a conference, you can bet that there will be a lot of great information on the latest in diabetes care. This year it …
Read More »AACE – New Diabetes Guidelines Based on Tailored Approach
AACE calls for a new guideline based on a tailored approach to treating type 2 diabetes while maintaining the use of an algorithm-based model…. Alan Garber, MD, PhD, of Baylor College of Medicine in Houston, and colleagues reported in Endocrine Practice and at the AACE meeting that, the new recommendations …
Read More »SGLT-2 Inhibitors: A New Modality for Treating Type 2 Diabetes
In this set of Homerun Slides, we give you a brief overview of the functioning of this new class of drugs, and get into the specifics of the first drug in its class approved by the FDA, canagliflozin (Invokana)…. Link to download (.ppt format): SGLT-2 Inhibitors: A New Modality for Treating …
Read More »SGLT2 Inhibitor Approvals and Updates
Johnson & Johnson’s SGLT2 canagliflozin (Invokana) has just received FDA approval, while Boehringer Ingelheim and Eli Lilly submit their SGLT2 inhibitor (empagliflozin) to the FDA…. U.S. health regulators have approved a new diabetes drug from Johnson & Johnson, making it the first in its class to be approved in the United States. …
Read More »EASD: SGLT-2 Demonstrates Reductions in Blood Pressure
Analysis demonstrated reductions in systolic blood pressure with empagliflozin, an investigational SGLT-2 inhibitor, independent of changes in blood glucose and weight in adults with type 2 diabetes…. Boehringer Ingelheim and Eli Lilly announced data from a pooled analysis of two phase IIb trials in adults with type 2 diabetes (T2D) …
Read More »EASD: SGLT-2 Added to Insulin Effective or Type 2’s with CVD
First results from phase 3 CANVAS trial show canagliflozin as add-on therapy to insulin lowered blood sugar levels in patients with type 2 diabetes at an elevated risk for cardiovascular disease…. Canagliflozin was also shown to be effective and generally well-tolerated in patients with type 2 diabetes aged 55 to …
Read More »SGLT-2 Inhibitor (Empagliflozin) Safe, Effective as Monotherapy
Empagliflozin reduced HbA1c, fasting plasma glucose and body weight when administered alone or as an add-on to metformin in patients with type 2 diabetes…. Adults with type 2 diabetes who had participated in one of two 12-week studies of empagliflozin (Boehringer Ingelheim, Eli Lilly) were treated for an additional 78 …
Read More »SGLT Inhibitors
History of the sodium-glucose co-transporter (SGLT) inhibitors by Erica Paul, PharmD, Graduate Intern University of Florida College of Pharmacy Back in the late 1800’s, a compound called phlorizin, found in the bark of apple trees, was isolated by French chemists. Since then it has been put to use in multiple …
Read More »Stop Using Sulfonylureas?
The ACP has issued a clinical practice guideline regarding use of oral agents in type 2 diabetes entitled, “Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians.”… This is important because despite new therapies, there hasn’t been a guideline from either …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.